Dual GH Secretagogue Stack — GHRH Analog + Ghrelin Mimetic
Buy CJC-1295 No DAC 5mg
The most studied growth hormone-releasing combination in peptide research. CJC-1295 extends GH pulse duration; Ipamorelin amplifies pulse amplitude — together producing synergistic GH output without cortisol elevation.
≥98% Purity
HPLC Verified
Research Grade
Lyophilized
Fast Shipping
Free $200+
Specifications
Mechanism of Action
CJC-1295 — GHRH Receptor Agonism
CJC-1295 (No DAC) is a synthetic analog of growth hormone-releasing hormone (GHRH) that activates GHRH receptors in the pituitary, stimulating GH release. 'No DAC' means it lacks the drug affinity complex that extends half-life in the DAC version — resulting in a pulse-like GH release pattern that more closely mimics natural pulsatility.
Ipamorelin — Ghrelin Receptor Agonism (GHSR)
Ipamorelin is a selective ghrelin receptor agonist (growth hormone secretagogue receptor — GHSR). It stimulates GH release through a completely different receptor than CJC-1295. Critically, Ipamorelin is highly selective — unlike other GH secretagogues (hexarelin, GHRP-6), it does not significantly elevate cortisol, prolactin, or ACTH.
Synergistic GH Pulse Amplification
CJC-1295 and Ipamorelin work on different but complementary GH-releasing pathways. When combined, they produce synergistic (not merely additive) GH output — studies show 2–5x greater GH secretion with the combination than either alone. This synergy is the primary reason for the widespread use of this stack in GH research.
Research Findings
Growth Hormone Pulse Augmentation
Combined GHRH + GHRP stimulation produces significantly greater GH output than either alone. Peak GH levels 2–5x higher with combination vs single agents in multiple studies.
Bowers et al., Endocrinology (1991); Clark et al., J Clin Endocrinol Metab (1997)
IGF-1 Elevation
Sustained GH release from CJC-1295/Ipamorelin protocols elevates serum IGF-1 levels over time. IGF-1 mediates many of GH's anabolic effects — muscle protein synthesis, fat mobilization, collagen production.
Ionescu & Frohman, J Clin Endocrinol Metab (2006)
Body Composition
Research in GH-deficient and normal subjects shows GHRH/GHRP combinations drive lean mass accretion and visceral fat reduction. Effects are more pronounced in subjects with blunted natural GH secretion (older individuals, those with metabolic dysfunction).
Veldhuis et al., Am J Physiol (2001)
Preclinical Safety Data
Ipamorelin has an excellent safety profile — Phase 1 studies showed no significant adverse effects and no elevation of cortisol, prolactin, or ACTH. CJC-1295 has been studied in human Phase 1/2 trials with a clean safety profile. The combination has been widely used in research without significant adverse event reports.
Research Dosing Protocols
From published literature — for research reference only.
Pre-Sleep Injection
CJC-1295 100–200mcg + Ipamorelin 100–200mcg
Once daily, 30–60 min before sleep
Timed to coincide with natural nocturnal GH pulse. Pre-sleep dosing maximizes GH pulse without food interference. Most common research protocol.
Morning + Pre-Sleep
100mcg each compound per dose
Twice daily
Two-injection protocol for more consistent IGF-1 elevation. Second injection is pre-sleep. Morning injection should be fasted.
Reconstitution Guide
- 1
This is a pre-mixed combination vial. Add 2 mL bacteriostatic water.
- 2
Inject water slowly down the vial wall. Swirl gently.
- 3
Resulting solution contains both CJC-1295 and Ipamorelin.
- 4
Refrigerate at 4°C after reconstitution. Use within 4 weeks.
- 5
For 200mcg total dose, draw 0.2mL from reconstituted vial.
Stacking Guide
IGF-1 LR3
CJC/Ipamorelin elevates GH and downstream IGF-1. Adding exogenous IGF-1 LR3 provides a direct, prolonged IGF-1 signal independent of GH pulsatility — useful in research requiring sustained anabolic drive.
BPC-157
GH secretagogue protocols increase training intensity and recovery demands. BPC-157 supports connective tissue integrity and reduces injury risk during high-frequency training protocols.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
DAC (Drug Affinity Complex) is a chemical modification that extends CJC-1295's half-life from ~30 minutes to ~8 days by binding to albumin. CJC-1295 No DAC produces a pulse-like GH release pattern more similar to natural pulsatility. No DAC is preferred in most research protocols for mimicking physiological GH secretion.
Why is Ipamorelin preferred over GHRP-2 or GHRP-6?
Ipamorelin is the most selective GH secretagogue available. GHRP-2 and GHRP-6 significantly elevate cortisol, prolactin, and ACTH alongside GH — complicating research protocols. Ipamorelin produces minimal cortisol and prolactin elevation, providing clean GH stimulation.
When should CJC-1295/Ipamorelin be injected?
Most research protocols time injection 30–60 minutes before sleep to coincide with the natural nocturnal GH pulse (largest daily GH release). Fasted injection is important — insulin (from recent food intake) blunts GH release and reduces effectiveness.
Research Disclosure: All products on this page are for laboratory research purposes only. They are not FDA-approved for human consumption, injection, or therapeutic use. Research findings cited are from preclinical and clinical studies and should not be interpreted as medical advice. Always consult a licensed healthcare provider.
Related Products
BPC-157 + TB-500 Blend 20mg
Buy BPC-157 + TB-500 Blend 20mg online — research-grade lyophilized peptide for laboratory use. Body Protection Compound-157 (15-amino-acid pentadecapeptide). ≥98% HPLC purity verified.
CAS: 137525-51-0
CJC-1295 No DAC 5mg
$49.99